EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Protein mechanism and therapeutic design in Parkinson's disease: A structural biology perspective

Danielle M Simons, Jean-François Trempe

Current Opinion in Neurobiology · 2025

DOI: 10.1016/j.conb.2025.103140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Opinion in Neurobiology, 2025. Verfasst von Danielle M Simons und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Parkinson Disease, Drug Design, Antiparkinson Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, Fonds de recherche du Québec, Fonds de recherche du Quebec Sante.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) remains one of the most elusive, progressive neurological diseases to treat due to an incomplete understanding of its pathology. Current symptomatic therapies revolve around alleviating symptoms with dopamine replacement therapy; however, this mode of treatment does not always provide long-term relief or address the underlying cause. Thus, there is still a need to better understand the mechanisms of proteins implicated in neurodegeneration as the key to developing disease-modifying treatments. Here we discuss recent advances in our understanding of six protein targets for PD therapy: α-synuclein, LRRK2, GBA1, PARKIN, PINK1, and USP30. For each, we highlight novel structures that shine light both on pathogenic mechanisms as well as novel therapies. We discuss drugs targeting these proteins that are in clinical trials, and how structures are used to improve them.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDrug DesignAntiparkinson AgentsHumansalpha-SynucleinAnimalsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Ubiquitin-Protein LigasesProtein KinasesGlucosylceramidasePTEN-Induced Putative Kinase

Substanzen

alpha-SynucleinLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Ubiquitin-Protein LigasesProtein KinasesGlucosylceramidaseAntiparkinson AgentsPTEN-Induced Putative Kinaseparkin proteinLRRK2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale, McGill University, Montreal, Quebec, Canada.
  • Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale, McGill University, Montreal, Quebec, Canada; Brain Repair and Integrative Neuroscience (BRaIN), Research Institute of the McGill…

Förderung

  • Canadian Institutes of Health Research
  • Fonds de recherche du Québec
  • Fonds de recherche du Quebec Sante

Zitieren

APA

Simons, D. M., & Trempe, J. F. (2025). Protein mechanism and therapeutic design in Parkinson's disease: A structural biology perspective. Current Opinion in Neurobiology. https://doi.org/10.1016/j.conb.2025.103140

Vancouver

Simons DM, Trempe JF. Protein mechanism and therapeutic design in Parkinson's disease: A structural biology perspective. Current Opinion in Neurobiology. 2025. doi:10.1016/j.conb.2025.103140

BibTeX
@article{Simons2025,
  author = {Simons, Danielle M and Trempe, Jean-François},
  title = {Protein mechanism and therapeutic design in Parkinson's disease: A structural biology perspective},
  journal = {Current Opinion in Neurobiology},
  year = {2025},
  doi = {10.1016/j.conb.2025.103140}
}
Kostenlos starten →